Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, today announced positive topline results from its pivotal Phase 3 DRAGON trial evaluating tinlarebant, an oral retinol binding protein 4 (RBP4) antagonist, for the treatment of adolescent Stargardt disease.
Merck (NYSE:MRK) unveiled groundbreaking final results from the Phase 3 KEYNOTE-B96 trial today at the ESGO 2026 Congress, demonstrating that a Keytruda-based regimen can extend the lives of patients facing one of the most aggressive forms of ovarian cancer.
ALX Oncology Holdings (NASDAQ:ALXO) reported fourth-quarter and full-year 2025 results on Friday, highlighting a fundamental shift toward a biomarker-driven strategy that could redefine patient selection for its immuno-oncology pipeline.
BrightSpring Health Services (NASDAQ:BTSG) posted a decisive fourth-quarter beat on Friday, capping a year of aggressive expansion with a return to full-year profitability.
Moderna (NASDAQ:MRNA) secured a landmark regulatory victory on Friday as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for mCOMBRIAX (mRNA-1083).
ANI Pharmaceuticals (NASDAQ:ANIP) posted record fourth-quarter net revenue of $247.1 million on Friday, a 29.6% increase over the same period last year.
Delek Logistics Partners (NYSE:DKL) reported fourth-quarter net income of $47.3 million on Friday, marking a significant year-over-year increase from the $35.3 million recorded in late 2024.
Amneal Pharmaceuticals (NASDAQ:AMRX) posted fourth-quarter net revenue of $814 million on Friday, exceeding Wall Street’s consensus estimate of $806 million.
Mesoblast (NASDAQ:MESO) reported financial results for the first half of fiscal year 2026 on Friday, highlighting a decisive transition from a clinical-stage biotechnology firm to a commercial-scale operator.
Novavax (NASDAQ:NVAX) reported fourth-quarter financial results that caught Wall Street by surprise, swinging to a profit during a period analysts expected to remain firmly in the red.
Privia Health Group (NASDAQ:PRVA) today announced fiscal year 2025 results that landed at or above the high end of its previously issued guidance, bolstered by strong provider implementation and a disciplined focus on value-based care.
U.S. Physical Therapy (NYSE:USPH) reported a significant expansion in its 2025 financial performance, driven by robust organic growth and a steady cadence of clinic acquisitions.
